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Purpose: International guidelines recommend the use of noninvasive ventilation in immuno-
compromised patients with acute respiratory failure (ARF). We analyzed failure rates and risk
factors for NIV failure in immunocompromised patients.
Methods: We retrospectively analyzed 120 immunodeficient patients treated with NIV in our
medical ICU from 2005 to 2011. We compared the clinical course and NIV failure rates. Further-
more, we compared patients with secondary respiratory failure due to those with Systemic
Inflammatory Response Syndrome (SIRS) of other than pulmonary origin to those with primary
pulmonary infiltrations.
Results: Regression analyses revealed high APACHE II score (p < 0.01), need for catechol-
amines (p < 0.05) and low paO2/FIO2 ratio (p < 0.05) as risk factors for NIV failure. Regarding
the underlying diseases, we could not find differences in NIV duration (pZ 0.07) and outcome
(pZ 0.44). 59.2% suffered from ARF due to lung infiltrations whereas 40.8% had secondary ARF
caused by sepsis of extrapulmonary origin. Patients with lung infiltrations had a longer stay on
ICU (16.3 vs 13.2 days; pZ 0.047) and showed a trend toward longer NIV duration (87  102 h
vs 65.6  97.8 h; p Z 0.056). The SIRS patients compared to pneumonia patients showed
a trend toward higher serum creatinine (1.63 mg/dL to 1.51 mg/dL; pZ 0.059), a higher rate
of renal failure (p < 0.01), higher APACHE II score (30.6e25.7, p < 0.01) and more frequently
needed catecholamines (p < 0.01). NIV failure rate (overall 55%) was not different.1 8344920; fax: þ49 251 8346190.
enster.de (P. Lebiedz).
2 Elsevier Ltd. All rights reserved.
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1510 P. Razlaf et al.Conclusions: Almost 50% of the immunocompromised patients treated with NIV did not require
intubation independent of the etiology of ARF. High APACHE II scores and severity of oxygen-
ation failure were associated with NIV failure.
ª 2012 Elsevier Ltd. All rights reserved.Introduction
For several years, NIV has been used for treatment of
neuromuscular diseases, chronic obstructive lung disease
(COPD), pulmonary edema, in immunodeficient and post-
surgical patients.1 Since invasive ventilation impedes the
risk of severe complications such as ventilator associated
pneumonia (VAP), barotrauma and lesions of the oro-
tracheal and laryngeal regions,2 NIV is a preferred alter-
native in the therapy of acute respiratory failure (ARF).
Immunosuppressed patients have a high risk of dying
from ARF.3,4 Due to rising numbers of bone marrow and
solid organ transplantations, there is a growing cohort of
immunosuppressed patients. Only few randomized studies
assessed the benefit of NIV in immunosuppressed patients.
Conti et al. showed in 1998, that NIV can be successfully
applied to patients with hematological disorders and acute
hypoxemic respiratory failure.5 These findings were
confirmed by Pancera et al., who demonstrated the
successful use of NIV in immunocompromised children.6
Another small study proved the benefit of CPAP ventila-
tion (continuous positive airway pressure) in neutropenic
patients admitted to the ICU due to respiratory distress.7
The cause of ARF might play an important prognostic
role. In immunodeficient patients, infections and drug-
related toxicity may lead to primary pulmonary infiltra-
tions.8 In contrast, sepsis or SIRS of other than pulmonary
origin often lead to secondary respiratory insufficiency due
to capillary leak syndrome, disturbances of capillary
perfusion, high oxygen consumption and elevated CO2
production. Studies comparing the outcome of immuno-
compromised NIV patients with regard to their underlying
disease are rare. Gruson et al. showed a prognostic
difference between bone marrow transplant recipients
with proven infectious pneumonia compared to those with
respiratory failure without proof of microbial origin.9
We herein present a large observational study to assess
the feasibility of NIV in immunocompromised patients with
different underlying diseases. Assuming that secondary
capillary leakage due to SIRS might potentially respond
faster to NIV than solid pulmonary infiltrations, we
compared outcome and failure rates of NIV in immuno-
compromised patients suffering from primary pulmonary
infection or secondary respiratory failure due to SIRS of
other than pulmonary origin.Patients and methods
After approval by our ethical board, we performed a retro-
spective survey consecutively including all adult immuno-
suppressed patients admitted to our medical ICU between
January 2005 and October 2011 and treated with NIV.Inclusion/exclusion criteria
We enrolled patients with hematological disorders
(leukemia, bone marrow infiltration), acquired immunode-
ficiency (e.g. AIDS), patients in leukocytopenia (due to
chemotherapy or bone marrow deficiency) and patients
receiving immunosuppressive drugs after bone marrow or
solid organ transplantation as well as autoimmune diseases.
Patients were eligible if they had respiratory distress
despite application of oxygen (>50% FIO2) and respiratory
rates >25e30/min and/or respiratory failure with a paO2/
FIO2 ratio (Horowitz index) < 200.
For patients with sole hypoxemic ARF, non-invasive CPAP
or bi-level positive airway pressure ventilation (BiPAP) was
applied. If a respiratory exhaustion occurred during CPAP,
we changed to BiPAP. Patients with primary hypercapnic
ARF were directly treated with BiPAP. Facial masks (Per-
formaTrak SE, Philips Respironics) were used in all
patients. For CPAP application we used the CF-800
(Dra¨ger) device with high-flow gas application. For BiPAP
we used either BiPAP Synchrony (Philips, Respironics),
BiPAP Vision (Philips, Respironics) or V60 (Philips,
Respironics).
Criteria for intubation or transfer to spontaneous
breathing
Criteria for aborting NIV and indication for endotracheal
intubation were an increase of hypoxemia despite NIV
(especially if paO2/FIO2 ratio decreased <200), severe
tachypnea or exhaustion under NIV, respiratory distress
under NIV despite mild analgo-sedation, progressive
encephalopathy, lack of cooperation, a Glasgow coma scale
(GCS) < 10, emesis or bleeding of the upper airways,
a rising serum lactate, severe organ malfunction or failure
leading to metabolic decompensation and progressive
manifest shock.
Criteria for transfer to spontaneous breathing were
stabilized clinical condition with reduced respiratory rate
(<20e25/min), sufficient blood gases under spontaneous
breathing with or without oxygen insufflations and subjec-
tive amelioration of respiratory distress.
Data analysis
We analyzed underlying diseases, kind of ARF (hypoxemic,
hypercapnic respiratory failure, pneumonia, sepsis, struc-
tural lung diseases etc), NIV duration, blood gases and
Horowitz index (paO2/FIO2) before, during and after NIV,
failure rates, occurrence of organ failure, catecholamine
dosages, APACHE II score,10 ICU days and outcome. Acute
kidney injury (AKI) was defined according to the Acute
Figure 1 Subdivisions of immunosuppressed patients
(primary intubation, status “do not intubate”, primary NIV).
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absolute increase in the serum creatinine concentration of
0.3 mg/dL (26.4 mmol/L) from baseline, a percentage
increase in serum creatinine concentration of 50%, or
oliguria of less than 0.5 mL/kg per hour for more than 6 h.11
The differentiation between the groups (pneumonia vs
sepsis) was done using a chest x-ray in all patients,
a thoracic CT-scan (89 patients, 74%) and bronchoalveolar
lavage (BAL) results (65 patients, 54%). Patients with known
extrapulmonary focus (e.g. catheter sepsis, peritonitis, or
urosepsis) and without relevant pulmonary infiltrations in x-
ray were classified as “sepsis of extrapulmonary focus”.
Statistical analysis
To test for differences between the groups, we used Man-
neWhitney U test for continuous parameters and Chi-
square test for categorical parameters. For analysis of
differences in continuous parameters between the under-
lying disease groups, we used the KruskaleWallis test. For
statistical analysis of linked samples, the Wilcoxon test was
applied. Univariate and multivariate regression analyses for
identification of risk factors for NIV failure were assessed
using a Cox regression analysis. The local significance level
was set to 0.05. An adjustment to multiplicity is not per-
formed. All analysis were performed using PASW 20
software.
Results
A total of 329 immunoincompetent patients were included
in our analysis. Of them, 197 needed a primary endotra-
cheal intubation and invasive ventilation during the obser-
vational period. They were not eligible for NIV due to
severe neurologic impairment, cardiac arrest, pharyngeal
or gastrointestinal bleeding or fulminant septic shock. Of
the 132 immunocompromised patients treated with NIV, 12
were excluded before start of data processing because they
were treated with NIV but due to bad prognosis or patient’s
provision they were regarded not eligible for endotracheal
intubation (Fig. 1).
Thus, we analyzed the data of 120 immunocompromised
patients (16e83 years), who had been admitted to our ICU
between 2005 and 2011 and were treated with NIV due to
ARF. Most of them (75%) suffered from hematological
malignancies such as leukemia and aggressive lymphomas
and underwent subsequent chemotherapy induced leuko-
cytopenia. Furthermore, we included patients with other
kinds of bone marrow failure (e.g. myelodysplastic
syndrome), after solid organ transplantation, as well as
those who received immunosuppressive drugs due to auto-
immune diseases. One patient suffered from AIDS.
Seventy-one patients (59.2%) were admitted with
respiratory failure caused by pneumonic or other lung
infiltrations, whereas 49 (40.8%) were transferred to ICU
with SIRS or sepsis of other than pulmonary origin and
developed secondary ARF. Non-infectious SIRS was mostly
due to leukemia-induced cytokine release. Most of the
septic patients without pulmonary focus had an abdominal
focus due to colitis, peritonitis or secondary infection due
to graft-versus-host disease (among others caused byEscherichia coli, Pseudomonas, Enterococcus, Candida).
These were followed by infections of intravasal catheters
(e.g. with Enterococcus, Staph aureus) and sepsis with
primary colonizing bacteria such as Streptococcus oralis.
Several patients classified as “sepsis”, lacked prove of
sepsis source or causing microbiologic agents, but showed
classical SIRS criteria, and were classified due to missing
pulmonary infiltrations.
The mean APACHE II score of all study patients was 28,
the mean Horowitz index at ICU admission was 179.Risk factors for NIV failure
High APACHE II score (p < 0.01), need for catecholamines
(p < 0.05) and low Horowitz index at ICU admission
(p < 0.05) were independent risk factors for NIV failure in
the univariate and multivariate analyses (Table 1a and b).
We divided the patients into 4 groups regarding their
paO2/FIO2 ratio at ICU admission (group 1: <100 e 12.5%;
group 2: 100e200 e 48.3%; group 3: 200e300 e 33.3%;
group 4: >300 e 5.8%). We found a significant association
between paO2/FIO2 group and NIV failure (p Z 0.05) but
not between paO2/FIO2 group and mortality (p Z 0.681)
(Fig. 2).Group comparison for underlying diseases
We found a remarkable difference in serum creatinine with
regard to the underlying diseases (p Z 0.002) with highest
values in patients after solid organ transplantation
(3.3  1.9 mg/dL) and with autoimmune diseases
(2.7  3 mg/dL) compared to patients with bone marrow
failure (1.3  0.8 mg/dL) and hematologic patients
(1.3  0.8 mg/dL). ICU duration was shorter in hematologic
patients (12.5  15.7 days) than in other groups
(p Z 0.011). Relevant differences in patients count in the
distinct diagnosis groups with most patients suffering from
hematologic malignancies (75%) have to be taken into
account for interpretation of these results (Table 2).
Table 1 a) Univariate analysis of risk factors for NIV
failure. b) Multivariate analysis of risk factors for NIV failure
(*significant).
p Hazard
rate ratio
95%
confidence
interval
a) Univariate analysis
APACHE II* 0.001 1.066 1.027 1.107
paO2/FIO2 at admission* 0.015 0.995 0.991 0.999
Need for catecholamines* 0.017 0.547 0.334 0.896
Gender 0.328 0.772 0.459 1.297
Age 0.360 0.993 0.978 1.008
Renal failure 0.052 0.607 0.367 1.005
Group (pneumonia/SIRS) 0.244 1.338 0.820 2.181
b) Multivariate analysis
Need for catecholamines* 0.047 0.561 0.317 0.993
APACHE II* 0.039 1.045 1.002 1.090
paO2/FIO2 at admission* 0.011 0.995 0.990 0.999
Acute renal failure 0.801 0.929 0.525 1.644
Continuous parameters: APACHE II, paO2/FIO2, age.
Categorical parameters: Need for catecholamines, gender,
renal failure, group (pneumonia/SIRS).
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We compared patients with primary pulmonary infiltrations
to those with secondary respiratory insufficiency due to
SIRS of other than pulmonary origin (Table 3). Patients with
primary lung infiltrations had a longer stay in the ICU (16.3
vs 13.2 days for SIRS patients; pZ 0.047; Fig. 3a). The SIRS
group showed a trend toward higher serum creatinine
(1.63 mg/dL  1.1) compared to the pneumonia patients
(1.51 mg/dL  1.38; p Z 0.059). Based on the AKIN defi-
nition, the SIRS patients had a higher rate of acute renal
failure (p < 0.01). They showed a higher APACHE II score
(30.6 vs 25.7, p < 0.01) and an elevated need for cate-
cholamines (p < 0.01). Comparison of NIV duration failed to
reach statistical significance (p Z 0.056), but showed
a trend toward longer NIV duration in pneumonia patients
(87  100 h compared to 65.6  97.8 h).Figure 2 NIV failure rate and mortality dependent on paO2/
FIO2 ratio.Blood pressure, heart rate, paO2/FIO2 index at ICU
admission as well as 1e2 h after stabilization under NIV,
days of renal replacement therapy, survival rates and NIV
failure rates did not differ significantly between both
groups (Table 3, Fig. 3).
CPAP vs BIPAP ventilation
A total of 34 (28.3%) patients were only treated with CPAP,
75 (62.5%) received BiPAP and in 11 (9.2%) cases, initial
treatment with CPAP was changed to BiPAP due to muscular
exhaustion. We found a significant higher rate of NIV failure
in the group with primary (45/75, 60%) or secondary (8/11,
72.7%) need for BiPAP than in the CPAP group (13/34,
38.2%; p < 0.05), what is most probably due to the fact,
that BiPAP was used in patients with severe respiratory
failure and additionally occurring respiratory exhaustion.
Amelioration of respiratory parameters during NIV
The paO2/FIO2 ratio approved significantly within the first
60e120 min after start of NIV (p Z 0.022) in all patients,
but did not improve further until the end of NIV
(pZ 0.397). Relevant differences with respect to cause for
ARF (pneumonia vs SIRS) could not be observed. PaCO2 did
not improve significantly, but hypercapnic respiratory
failure was extremely rare in our patients that mainly
suffered from primary hypoxemic ARF.
Outcome
A total of 66 (55%) patients needed an endotracheal intu-
bation during the treatment. Causes for intubation were
respiratory exhaustion under NIV in 51 patients (77.3%),
severe shock in 9 (13.6%), CPR in 4 (6.1%) and progressive
neurological impairment in 2 (3%) of the patients. In 54
(45%) patients, a transfer from NIV to spontaneous
breathing could be achieved. The mean ICU duration was
15.1 days, mean NIV duration was 78 h. The overall
mortality was 52.5% (n Z 63), from these 48 patients died
on ICU. In most of them (82.5%) the death was caused by
progressive hemodynamic failure, 4.8% died from respira-
tory causes, in two patients, therapy was abandoned, in
6.3% cases, cerebral disorders lead to decease. Two deaths
remained unclear. Four patients (6.3%) died during NIV, 44
(69.8%) under invasive ventilation and 15 (23.8%) suffered
from fatal secondary complications after discharge from
ICU.
The outcome of patients with regard to their underlying
disease is shown in Table 2, that with regard to the cause of
pulmonary failure (pulmonary infiltration vs SIRS) is dis-
played in Table 3.
Discussion
While plenty of reports describe the benefit of NIV for COPD
patients and cardiogenic lung edema,12 studies investi-
gating the use of NIV in immunosuppressed patients are
rather rare. To our knowledge, this is one of the largest
studies assessing the outcome of immunodeficient patients
Table 2 Patient’s characteristics and group comparison with regard to underlying diseases (values are presented as
mean  SD, * Z significant, ** Z highly significant).
All Leukemia/lymphoma Bone marrow
failure
Solid organ
transplantation
Autoimmune
diseases
HIV p
N 120 90 (75%) 12 (10%) 13 (10.8%) 4 (3.3%) 1 (0.8%)
Female 36.7% 34 (37.8%) 5 (41.7%) 3 (23.1%) 2 (50%) 0 0.718
Age (years) 53  14.9 53.3  14.2 47.3  21.1 59.7  10.4 41.2  15.2 46 0.117
APACHE II 27.7  7.5 28.2  7.4 25.2  6 26.8  9 26.2  7.3 32 0.650
paO2/FIO2 179.3  76.6 177.7  68.9 207.6  88.5 179.8  112.3 102.2  10.7 114.7 0.118
PaCO2 (mmHg) 40.7  14.5 40.3  11.4 38.6  6.8 30.4  4.6 64.4  47.4 44 0.230
Body temperature (C) 37.1  1.7 37.2  1.7 37.2  2 36  1.5 37  1.1 39.3 0.140
Creatinine (mg/dL) 1.56  1.27 1.3  0.83 1.3  0.8 3.3  1.9 2.7  3 0.6 0.002**
AKI 37 (30.8%) 28 (31.1%) 4 (33.3%) 4 (30.8%) 1 (25%) 0 0.969
RRT 19 (15.8%) 13 (14.4%) 3 (25%) 2 (15.4%) 1 (25%) 0 0.856
Duration of RRT (days) 0.4  1.1 0.31  0.96 1.1  2 0.23  0.6 0.5  1 0 0.756
ICU duration (days) 15.1  18.2 12.5  15.7 21.4  16 21.7  31.1 26  9.3 43 0.011*
NIV duration (h) 78.2  100 82.1  99.8 116  143.8 37.2  42.9 28.8  43.3 8.8 0.068
NIV failure rate 66 (55%) 48 (53.3%) 8 (66.7%) 5 (38.5%) 4 (100%) 1 0.179
Lethality 66 (55%) 47 (52.2%) 9 (75%) 7 (53.8%) 2 (50%) 0 0.442
Death at ICU 48 (40%) 35 (38.9%) 9 (75%) 2 (15.4%) 2 (50%) 0 0.186
Discharge from hospital 56 (46.7%) 43 (47.8%) 3 (25%) 6 (46.2%) 2 (50%) 1 0.442
ICU Z intensive care unit, AKI Z acute kidney injury, RRT Z renal replacement therapy.
NIV in immunoincompetent patients 1513treated with NIV, and moreover the first study comparing
the clinical course of immunoincompetent patients under
NIV with pulmonary infiltrations to those with SIRS or sepsis
of other than pulmonary origin. We showed in a large cohort
that in approximately half of the patients admitted to ICU
with ARF, NIV was successfully used eventually leading to
discharge from hospital. The cause for respiratory failureTable 3 Comparison between patients with primary respirator
presented as mean  SD, *Z significant, **Z highly significant; va
a trend).
All
N 120
% Female 36.7%
Age (years) 53  14.9
APACHE II 27.7  7.5
paO2/FIO2 admission 179.3  76.6
paO2/FIO2 after 1e2 h NIV 190.7  86.6
PaCO2 (mmHg) 40.7  14.5
pH 7.36  0.16
Body temperature (C) 37.1  1.7
MAP at admission (mmHg) 77.7  31
Creatinine (mg/dL) 1.56  1.27
AKI 37 (30.8%)
RRT 19 (15.8%)
Duration of RRT (days) 0.4  1.1
Need for catecholamines 38 (31.7%)
ICU duration (days) 15.1  18.2
NIV duration (h) 78.2  100
% intubation Z NIV failure 66 (55%)
Lethality 66 (55%)
Death at ICU 48 (40%)
Discharge from hospital 56 (46.7%)
ICU Z intensive care unit, AKI Z acute kidney injury, RRT Z renal r(pulmonary infiltrations vs sepsis of non-pulmonary origin)
did not influence NIV failure rates, neither did the under-
lying disease. Severity of illness and low oxygenation
indices at ICU admission are risk factors for NIV failure in
immunodeficient patients.
First feasibility data for NIV in immunosuppressed
patients was presented by Conti et al. 19985 in a pilot studyy infiltrations and SIRS of extrapulmonary origin (values are
lues marked with (*) were only borderline significant, showing
Pneumonia SIRS p
71 (59.2%) 49 (40.8%)
20 (28.2%) 24 (49%) 0.02*
52.5  15.7 53.6  15.8 0.96
25.7  7 30.6  7.2 0.001**
172.4  76.2 188.8  77 0.189
181.2  66.7 205.3  109.8 0.297
39.2  9.3 43.1  20.1 0.782
7.38  0.13 7.33  0.2 0.4
37  1.7 37.2  1.7 0.41
80.1  29.4 74.2  32.8 0.119
1.51  1.38 1.63  1.1 0.059(*)
15 (21.1%) 22 (44.9%) 0.006**
11 (15.5%) 8 (16.3%) 0.902
0.45  1.25 0.27  0.76 0.936
14 (19.7%) 24 (49%) 0.001**
16.3  19.4 13.2  16.5 0.047*
87  102 65.6  97.8 0.056(*)
38 (53.5%) 28 (57.1%) 0.695
41 (57.7%) 24 (59%) 0.418
28 (39.4%) 20 (40.8%) 0.642
30 (42.3%) 25 (51%) 0.418
eplacement therapy, MAP Z mean arterial blood pressure.
Figure 3 a) ICU duration, b) NIV failure rate and outcome of
NIV patients.
1514 P. Razlaf et al.of 16 patients. In this study, a rapid improvement of gas
exchange was reached in 15 of 16 patients. The rate of
intubation was extraordinarily low (6%), this may be influ-
enced by the relatively low SAPS II score of 13.4.
In our opinion, the present study clearly supports the use
of NIV even in critically ill immunosuppressed patients with
severe pneumonia and sepsis.
Anyhow, there are certain limitations of this report.
Above all, it represents a retrospective observational
analysis and not a prospective study with all limitations
involved. With regard to pre-existing data about the good
results of NIV in immunocompromised patients,13 a primary
randomization seems questionable. A comparison to the
immunosuppressed patients, that needed a primary intu-
bation, seems not reasonable, because these patients
suffered from different disorders (neurologic impairment,
CPR and others) and not from ARF. Furthermore, during the
long observation period, many different persons were
involved in patients’ therapy, so individual decisions for or
against NIV or disruption of NIV have to be taken in account.
Use of NIV compared to oxygen insufflations only
In 2001, Hilbert and colleagues showed that the outcome of
immunosuppressed patients with fever, pulmonary infiltra-
tions and ARF improved when NIV was used instead ofoxygen application via mask.13 In this randomized study of
52 patients, a significant reduction of serious complications
(13 vs 21, p Z 0.02) and death in hospital (10 vs 18,
p Z 0.03) was observed in the NIV group. In accordance,
patients after solid organ transplantation were reported to
benefit from NIV compared to oxygen insufflations.14 Other
reports displayed different results. Thus, a recent
randomized study by Wermke et al. showed disappointing
results in a defined group of patients with ARF after allo-
geneic stem cell transplantation, although a significant and
rapid improvement of gas exchange was observed.15
Although, the benefit of NIV compared to oxygen insuf-
flations is discussed controversially, adverse events of NIV
in immunocompromised patients have seldom been re-
ported. In our study, we included only patients with severe
respiratory failure under oxygen application and need for
mechanical ventilation. A comparison to patients with sole
oxygen insufflations was not done. Few further patients
(approximately 10 per year) after bone marrow trans-
plantation in our hospital received NIV instead of oxygen
insufflations via mask at our bone marrow transplantation
ward. They were not included due to a lack of continuous
blood gas analysis and monitoring.
Non-invasive and invasive ventilation
Confalonieri et al. performed a study in 48 AIDS patients and
found a significant better outcome in AIDS patients with
Pneumocystis carinii pneumonia treated with NIV compared
to invasive ventilation.16 Another recent retrospective
analysis found an improved outcome in patients with hema-
tologic malignancies treated with NIV compared to those
with invasive mechanical ventilation.17 Limitation of this
retrospective multicenter study was the fact, that patients
who primarily needed invasive ventilation probably showed
more co-morbidities. In contrast, a different trial failed to
identifyNIV compared to invasive ventilation to influence the
overall patient’s outcome in hematologic patients with need
for ventilator support.18 In this retrospective study only few
patients (26 of 166) were treated with NIV, so the evaluation
of the impact of NIV on clinical course is very limited. In
addition, the 26 patients were included over a five years
period, and 42% of them had DNR decisions.
Whether NIV might negatively influence the patient’s
outcome by delaying necessary invasive ventilation is still
under discussion. Gristina found unsuccessful NIV to be
associated with 70% mortality in ALI/ARDS patients but also
reported a similar overall mortality in the patient’s group
with early compared to later endotracheal intubation.17 This
report matches our results showing a lower paO2/FIO2 ratio
being associated with a higher NIV failure rate. We found
highest intubation rates in patients with low oxygenation
index (paO2/FIO2 <100 and 100e200) but no association
between severity of respiratory failure and mortality.
NIV failure
Our study revealed that co-morbidities defined by high ICU
scores (APACHE II) and need for catecholamines were
associated with higher risk for NIV failure in immunosup-
pressed patients, which is consistent with the previous
NIV in immunoincompetent patients 1515studies.7,19 In our opinion, the prove of higher NIV failure
rates depending on severity of illness should not prevent
the clinician from trying NIV in critically ill patients taking
the contraindication into account.
In accordance with the recent study by Phua et al.20 in
patients with bronchiectasis, we additionally found a low
Horowitz index (paO2/FIO2) at ICU admission to be
a predictor of NIV failure. The underlying disease did
neither influence the course during NIV therapy, the NIV
failure rate nor the patients’ outcome.
Compared to former studies13 as well as during the years
in our own ICU (2005e2011) we found rising NIV success and
overall survival rates which is most probably due to growing
experiences with NIV as well as improvement of general ICU
therapy and antimicrobial treatment.NIV success rates dependent on the cause for
respiratory failure
Assuming that sepsis and SIRS of other than pulmonary
origin induce secondary respiratory insufficiency by capil-
lary leakage and enhanced need for oxygens as well as high
CO2 production, whereas primary respiratory failure is
caused by direct lung infiltration, we examined the
outcome of NIV in these different pathogenetic groups. ARF
due to SIRS is caused by capillary leak as well as microcir-
culatory disorders, endothelial dysfunction and oxidative
stress caused by cytokines, complement system and coag-
ulatory disturbances. Pulmonary infiltrations are caused by
inflammatory cell migration into the pulmonary tissue.
Pneumonic infiltrations directly influence the alveolar gas
exchange. In severe leukocytopenia, pulmonary infiltra-
tions may go along without visible pulmonary infiltrations.
Although these sepsis cases are of pulmonary origin, lack of
leukocyte infiltrations also prevents disturbance of alveolar
gas exchange.
These differences in pathogenesis of ARF are also asso-
ciated with differences between the groups regarding other
organ dysfunction, in our study being expressed by a higher
serum creatinine and acute renal failure rate in the SIRS
group.
Due to the pathogenesis, we assumed a different effect
of non-invasive positive pressure ventilation on the
pulmonary gas exchange knowing, that cardiac lung edema
can be easily and quickly treated by NIV.
To our knowledge, this comparison has never been done.
A single study by Fartoukh et al. has focussed on use of NIV
in pulmonary capillary dysfunction by sickle cell anemia.21
We could not detect significant differences in NIV failure
and lethality rates dependent on the cause for respiratory
failure. Patients with primary lung infiltrations showed
a borderline-significant longer need for NIV and longer ICU
stay compared to those with SIRS which might be ascribed
to the assumed longer duration for healing of the cellular
lung infiltrations.Conflict of interest
No conflicts of interests have to be declared.References
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